Drugs / CTX-187
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07708116 | Jun 2026 → Dec 2027 expected | bacterial infectious disease, bronchiectasis | Centauri Therapeutics Limited | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-03-10 | Centauri Therapeutics Limited | Regulatory Centauri Therapeutics granted FDA QIDP status for CTX-187 treatment of Gram-negative bacterial infections centauritherapeutics.com ↗
today announced that the Company’s lead clinical candidate in the ABX-01 programme, CTX-187, has received Qualified Infectious Disease Product (QIDP) designation from the US Food and Drug Administration (FDA). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-03-10 | Centauri Therapeutics Limited | Centauri Therapeutics granted FDA QIDP status for CTX-187 treatment of Gram-negative bacterial infections centauritherapeutics.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CTX-187 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07708116 ↗ |
| Route | Intravenous | “CTX-187 will be administered via IV infusion.” NCT07708116 ↗ |